Valuation : TaiGen Biopharmaceuticals Holdings Limited

Market Cap 6.18B 195M 168M 159M 144M 271M 18.66B 272M 1.89B 728M 9.5B 734M 718M 30B P/E 2024
-213x
P/E 2025 223x
Enterprise Value 5.2B 164M 142M 134M 122M 228M 15.71B 229M 1.59B 613M 7.99B 618M 604M 25.26B EV / Sales 2024
48.2x
EV / Sales 2025 33x
Free-Float
53.82%
Yield 2024 *
-
Yield 2025 -
08-26 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-05 InSilico Out-licensed Drug ISM4808 Begins Clinical Trial MT
11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-21 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) added to S&P Global BMI Index CI
25-08-19 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-07-31 TaiGen Biopharmaceuticals Holdings Limited(TPEX:4157) dropped from S&P Global BMI Index CI
25-05-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-13 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-01 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-14 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
1 day-2.03%
1 week-0.80%
Current month-3.34%
1 month-4.19%
3 months-1.81%
6 months-22.84%
Current year-35.22%
1 week 8.63
Extreme 8.63
9.28
1 month 8.63
Extreme 8.63
9.34
Current year 7.73
Extreme 7.73
16.4
1 year 7.73
Extreme 7.73
16.4
3 years 7.44
Extreme 7.44
17.25
5 years 7.44
Extreme 7.44
21.05
10 years 7.44
Extreme 7.44
38.7
Manager TitleAgeSince
Chief Executive Officer - 2019-01-01
Director of Finance/CFO - 2016-03-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman - 2001-03-31
Director/Board Member - 2013-04-28
Director/Board Member - 2009-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-0.80%-7.56%-41.94% 195M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.86%-5.72%+19.12%+32.12% 350.5B
Weighted average by Cap. -0.51%-4.42%+30.96%+54.94%

Financials

2024 2025
Net sales 151M 4.76M 4.1M 3.89M 3.52M 6.61M 455M 6.64M 46.15M 17.75M 232M 17.89M 17.5M 732M 259M 8.2M 7.07M 6.69M 6.07M 11.38M 784M 11.44M 79.49M 30.57M 399M 30.81M 30.13M 1.26B
Net income -38.58M -1.22M -1.05M -995K -902K -1.69M -117M -1.7M -11.82M -4.55M -59.29M -4.58M -4.48M -187M 45.18M 1.43M 1.23M 1.17M 1.06M 1.98M 136M 1.99M 13.84M 5.32M 69.43M 5.36M 5.25M 219M
Net Debt -961M -30.39M -26.18M -24.79M -22.47M -42.16M -2.9B -42.37M -294M -113M -1.48B -114M -112M -4.67B -978M -30.91M -26.63M -25.21M -22.85M -42.88M -2.95B -43.09M -299M -115M -1.5B -116M -114M -4.75B
Logo TaiGen Biopharmaceuticals Holdings Limited
Taigen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs. The Company operates through two segments. The New Drug Research and Development and Drug Sales segment is mainly engaged in the research, development, manufacturing and sales of various new drugs and cell preparations. The Other segment provides medical technology consulting services. The Company's main products are Nemonoxacin and TG-100. Nemonoxacin is mainly used for nosocomial pneumonia infections, diabetic foot infections, urinary tract infections and complicated skin infections. TG-100 is mainly used for type A, type B influenza and avian influenza.
Employees
-
Date Price Change Volume
26-09-11 NT$8.680 -2.03% 1,020,547
26-09-10 NT$8.860 -1.88% 838,833
26-09-09 NT$9.030 +0.22% 604,974
26-09-08 NT$9.010 -1.74% 1,060,732
26-09-07 NT$9.170 +4.80% 1,924,853
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 4157 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!